Clinical trial
Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma
NCT00020111 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00020111 |
|---|---|
| Title | Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma |
| Official title | Phase I Trial and Pharmacokinetic Study of Arsenic Trioxide in Pediatric Patients With Refractory Leukemia or Lymphoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma |
| Intervention type | Drug |
| Interventions | arsenic trioxide |
| Start date | Mar 1, 2000 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 29, 2015 |
| Countries | Australia, Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: